Dianthus Therapeutics (DNTH) Short-term Investments (2017 - 2025)

Dianthus Therapeutics' Short-term Investments history runs 9 years deep, the most recent figure standing at $353.2 million for Q4 2025.

• On a quarterly basis, Short-term Investments rose 39.91% year-over-year to $353.2 million in Q4 2025; TTM through Dec 2025 was $353.2 million, a 39.91% increase from a year earlier, with the FY2025 full-year figure at $353.2 million, up 39.91% from the prior year.
• Short-term Investments climbed to $353.2 million in Q4 2025 per DNTH's latest filing, from $346.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $353.2 million in Q4 2025 and bottomed at $1.8 million in Q1 2023.
• The 5-year median for Short-term Investments is $64.7 million (2022), against an average of $119.8 million.
• Across the five-year window, Short-term Investments tumbled 97.9% in 2023 and surged 2557.98% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $45.3 million in 2021, then surged by 32.8% to $60.1 million in 2022, then slumped by 31.16% to $41.4 million in 2023, then jumped by 509.88% to $252.4 million in 2024, then jumped by 39.91% to $353.2 million in 2025.
• Per Business Quant, the three latest DNTH Short-term Investments figures stand at $353.2 million (Q4 2025), $346.6 million (Q3 2025), and $244.2 million (Q2 2025).